CRL for LNTH-2501 (Ga-68 edotreotide) (Jun 26 2026) — unresolved third-party manufacturing; no efficacy/safety issues
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (1/12/26) through T+5. Run-up high $109.8 on 6/26/26, low $64.25 on 1/23/26 (T-120 to T-1). FDA decision 6/29/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-06-29
OutcomeCRL
Drug / candidateLNTH-2501 (Gallium-68 edotreotide)
IndicationNeuroendocrine tumors (NETs) in adult and pediatric patients
CompanyLantheus Holdings
Market-cap tierMid
120-day run-up (T-120→T-1)+59.2%
Cohort decision-day move (history)±2% median
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction.